Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. develops and commercializes therapeutic products for life-threatening conditions, with a U.S. commercial focus in institutional settings of care. Its recurring news centers on DefenCath, a taurolidine and heparin product used to prevent catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters, and on the specialty pharmaceutical portfolio added through the completed Melinta Therapeutics acquisition.
Company updates also cover anti-infective and hospital-focused products such as MINOCIN for Injection, REZZAYO, VABOMERE, ORBACTIV, BAXDELA and KIMYRSA, as well as TOPROL-XL. News themes include operating and financial results, commercial execution, clinical and regulatory disclosures for expanded product uses, shareholder voting matters, governance updates, investor conference activity and capital actions such as share repurchase authorization.
CorMedix Therapeutics (Nasdaq: CRMD) will participate in two upcoming investor conferences in New York, featuring fireside chats and investor meetings.
The company presents at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026, with live webcasts available.
CorMedix Therapeutics (Nasdaq:CRMD) reported Q1 2026 net revenue of $127.4 million, net income of $38.6 million, and adjusted EBITDA of $70.0 million. DefenCath generated $97.5 million, including a non-recurring $9.0 million benefit, while the Melinta portfolio contributed $29.9 million.
The company raised 2026 net revenue guidance to $325–$345 million and adjusted EBITDA guidance to $115–$135 million. Positive Phase III topline results for REZZAYO in prophylaxis support an sNDA filing targeted for the second half of 2026. Cash and short-term investments totaled $178.1 million.
CorMedix (Nasdaq: CRMD) will report first quarter 2026 financial results for the period ended March 31, 2026, before the market opens on Thursday, May 14, 2026. The company will host a corporate update conference call at 8:30am Eastern Time with domestic and international dial-in numbers and a webcast.
CorMedix (Nasdaq: CRMD) announced positive Phase III topline results from the global ReSPECT trial of REZZAYO (rezafungin) for prophylaxis of invasive fungal diseases in adult allogeneic HSCT patients. The study met its primary endpoint, showing non-inferiority for fungal‑free survival at Day 90: 60.7% for rezafungin vs 59.0% for standard antimicrobial regimen.
Results reported comparable efficacy for Candida, Aspergillus and Pneumocystis, comparable mortality, and a favorable safety profile with fewer toxicity‑related discontinuations and reduced drug‑drug interactions. Mundipharma sponsored the trial; a pre‑NDA meeting is planned with FDA, targeting an sNDA submission in 2H26.
CorMedix (Nasdaq: CRMD) said senior management will participate in a fireside chat and investor meetings at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. The fireside chat is scheduled for April 14, 2026 at 3:00pm ET and will be available via webcast.
CorMedix (Nasdaq: CRMD) reported strong fourth-quarter and full-year 2025 results: Q4 net revenue $128.6M, pro forma 2025 revenue $401.3M, and full-year net income $163.0M. Q4 adjusted EBITDA was $77.2M. The company reiterated 2026 guidance and announced a $75M share repurchase program.
Cash and short-term investments were $148.5M at year-end; key clinical readouts for REZZAYO are expected in Q2 2026.
CorMedix (Nasdaq: CRMD) will report its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before the market opens on Thursday, March 5, 2026. The company will host a corporate update conference call at 8:30am Eastern Time.
Investors can join by domestic phone 1-844-676-2922, international phone 1-412-634-6840, or via webcast.
CorMedix (Nasdaq: CRMD) said senior management will present and meet investors at three healthcare conferences in March 2026: Leerink Partners (March 10), Citizens Life Sciences (March 11) and Barclays (March 12).
The company listed formats (fireside chats and one-on-one meetings) and webcast links where available for investor access.
CorMedix Therapeutics (Nasdaq: CRMD) announced a Board‑authorized share repurchase program to buy up to $75 million of common stock through December 31, 2027. The company expects repurchases could begin as early as Q1 2026 and had approximately $150 million cash and 79.3 million shares outstanding as of Dec 31, 2025.
Repurchases may occur via negotiated transactions, block trades, open market purchases or trading plans and are subject to market conditions, liquidity, cash flow and applicable securities laws. The program is discretionary and may be suspended or discontinued.
CorMedix Therapeutics (Nasdaq: CRMD) will host an in-person and virtual Analyst Day in New York on February 10, 2026, from 1:00 PM to 3:00 PM Eastern.
The company will provide portfolio and pipeline updates, outline growth drivers and upcoming milestones, and feature KOLs and senior management discussing REZZAYO (Phase III) and DefenCath (Phase III).